This political and social info is just a part of my DD on
This political and social info is just a part of my DD on LL which I'd usually leave out with other biotech stocks. LL is different since it may present a serious challenge to the very existing system of power/money way beyond Big Pharma. If our hopes for LL power over Cancer and other mass lethal diseases come true this challenge may rise to the status of existential. Covid is just a tip of the iceberg. It is the possible prophylactic effect of LL that can turn the social-political situation upside down. Let's take for illustration just a relatively marginal case of Philippines.
In his last public appearance Dr. Richard Nicholas pointed out that none of his Filipino patients he'd treated with LL developed LH Covid symptoms. He emphasized the importance of this fact by repeating this statement in native Tagalog. Now I am trying to imagine the effect of this on two Filipino groups: the VIP class and the people. Had I belonged to the former I would make sure to receive LL at the earliest signs of COVId infection and this is why I'd be in support of the existing LL supply system to Philippines giving my VIP class access to the molecule, only perhaps making it somewhat less time consuming. But if I am one of those 20% with USD 175 a month or even a member of the middle-class with the family income between USD450-1500 I wouldn't be happy at all with the way the system works. Still I may find some comfort in the relative accessibility of the Chinese vaccine or in the hope of having a mild case and even the idea that all pandemics end sooner or later.
But what if the 99% of Filipino society learns that LL is more effective than any other drugs against cancer and a host of other lethal mass deceases, that it empowers our immune system to prevent the development of these diseases and that LL is absolutely safe? Unlike pandemics, cancer is going nowhere. It's growing undetected right now in the bodies of millions around the world and millions are dying of it right now. And the world population is getting greyer and more susceptible to deadly ills with each passing day. And Professor Sison's Communist Party tell the Filipino poor (the majority of the country) that only by liberating their country of Yankee imperialism--which incidentally includes the FDA and BPharma--a health system for the people is possible... This is what I call LL's systemic challenge.
8
CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...
Continue Reading
No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...
Continue Reading
Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...
Continue Reading
What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...
Continue Reading
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...
Continue Reading
A New Gadget for the Diehard Fan Fanatics, gather 'round. There's an innovation rolling out that's looking to marry the good old alarm clock radio with the rush of game day fever! Over in Pittsburgh, an inventor's cooking up something that every loyal sports fan might soon find irresistible—a Sports Clock Radio, bringing the stadium experience to your living room or...
Continue Reading
Revamping School Memories for the Tech Age In a world where every facet of life is digitally chronicled, it's about time schools got on board the archival train in a dynamic way. That's where Rocket Alumni Solutions steps in, breathing fresh life into those dust-gathering yearbooks and sepia-toned photos. Tackling History Collection by Collection Think you can throw a...
Continue Reading
The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...
Continue Reading
Push Your Expectations: Pine AI Takes the Stage Here's a twist in tech worth a double take. Pine AI is shaking up the AI world with a brash blend of video genius and actual chat capabilities. Somehow, merely weeks after setting the tech scene ablaze with its AI-focused computer, it's already rolling out new applications faster than hotcakes on a skillet. But let’s chew...
Continue Reading
Top 5 Most Recently Viewed Articles
Investors Targeting Crocs Encouraged to Join Class Action Faruqi & Faruqi, LLP, a prominent name in securities litigation, is reaching out to investors who have experienced significant losses in Crocs stock to participate in an emerging federal class action lawsuit. The firm is particularly concerned with those who incurred losses exceeding $50,000. The deadline to assume...
Continue Reading
Chaoyang: A Tapestry of Global Life Taking a stroll through Beijing's Chaoyang district, you'd catch more than just a glimpse of its soaring skyscrapers or riverside parks—you're stepping into a melting pot of cultures and modern business ethos. It’s not puffery when they say this district marries the world’s diversified cultures with dynamic business environments;...
Continue Reading
Foot Locker on the Path to Recovery Recent analysis by Needham's analyst Tom Nikic illustrates a promising outlook for Foot Locker, Inc. (NYSE: FL), highlighting how the company is positioned for earnings recovery in the coming year. The strengthened partnership with Nike, along with growth in non-Nike brands, and recent investments in selling, general and administrative...
Continue Reading
The Rising Trend of Milking Automation Market The milking automation market is currently experiencing a significant transformation, with estimates projecting a growth to USD 3.68 billion by 2030. This steady rise reflects a robust CAGR of 7.1% from an initial valuation of USD 2.61 billion. Factors driving this expansion include increasing demand for milk, labor shortages...
Continue Reading
Immatics Updates on ACTengine® IMA203 for Melanoma Patients Overview: Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in the development of T cell-redirecting immunotherapies, has recently announced significant advancements in its clinical trial of ACTengine® IMA203. The focus of this update is on the therapy's application in...
Continue Reading